Fig. 1

APC and T cell count in FTY-treated RRMS patients. a Relative and absolute cell count in slanDCs (A/B), CD1 + DCs (C/D), and monocytes (E/F) were evaluated at baseline (BL), 4, 12, and 24 months (M) follow-up of 35 FTY-treated RRMS patients. In parallel absolute cell count of CD4+ T cells, proportion of CD39 + FoxP3+ Treg cells and CD154 + IL17+ Th17 cells was examined (G–I). Ratio of Treg/Th17 is depicted (K). b Activation and maturation markers of APC during FTY treatment. Expression of activation and co-stimulatory surface markers were analyzed at baseline (BL), 4, 12, and 24 months (M) in FTY-treated RRMS patients in slanDCs (A–D), CD1 + DCs (E–H), and monocytes (I–M). Mean values ± SEM are presented. Bonferroni’s correction for compared pairs was used for multiple testing. Asterisks indicate a statistically significant difference (*p < 0.05, **p < 0.01, ***p < 0.001)